- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00293943
Randomized Trial of Two Different Strategies to Treat Paroxysmal Atrial Fibrillation
A Randomized Trial to Investigate the Significance of Complete Versus Incomplete Electrical Isolation of Pulmonary Veins by Radiofrequency-induced Linear Lesions
The purpose of this study is to investigate the significance of complete versus incomplete electrical isolation of pulmonary veins by radiofrequency-induced linear lesions in patients with paroxysmal atrial fibrillation.
The study hypothesis ist that the complete linear PV isolation ablation is superior to the non-complete linear PV isolation on the outcome of patients with idiopathic drug-refractory atrial fibrillation. As a second hypothesis in this adaptive study design, the non-inferiority of the complete linear PV isolation strategy will be tested.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Atrial fibrillation can be cured by elimination of triggering events such as atrial extrasystoles originating from the pulmonary veins (PV) by selective or linear radiofrequency current applications.
Although electrical isolation can be demonstrated by a circumferential mapping catheter positioned at the PV ostium, longterm effect of such EP-guided PV isolation procedures achieve about 60-70% of stable sinus rhythm during follow-up even in experienced centers. Re-investigation of symptomatic patients after initially electrically isolated PVs demonstrated a substantial amount of PV reconduction which might explain the arrhythmia recurrence.
Although it was demonstrated that linear lesions for PV isolation is superior to the selective ablation approach, conflicting data exists on the necessity to achieve complete linear lesions. The groups of Pappone et al and Oral et al both published a success rate of more than 90% of patients in sinusrhythm irrespective of the line completeness, which both groups estimated to be reached in only 30% of cases.
Several advantages and disadvantages could advocate for either the complete versus the incomplete ablation strategy: Performing the complete EP-guided linear PV isolation strategy might take longer (mean duration 4.5 hours vs about 2 hours) and could thereby potentially result in a higher risk of procedure-associated complications (air embolism, thrombus formation, perforation). In addition, three transseptal sheaths might increase the risk of tamponade and might aggravate the ability to safely navigate catheters in the left atrium. Certainly, the procedure costs are higher, since in addition to the 3D mapping system two circular mapping catheters are mandatory to facilitate the lesion deployment and avoidance of intra-PV ablation.
In addition, an ablation strategy that does not depend on complete line deployment may be sufficient to achieve stable sinus rhythm. Although, additional linear lesions between the PV isolation segments and towards the mitral annulus as proposed by several centers with incomplete linear PV isolation approaches might not be necessary to achieve stable sinus rhythm. Potential complications such as atrio-esophageal fistula formation could be avoided if no additional lesions eg. along the LA roof would be necessary. Both the costs of the additional material (transseptal sheaths, circular mapping catheters) and the shorter procedure duration (about 2 hours) would be reduced. On the other hand, these costs would be balanced by the reduced number of re-ablation, if incomplete PV isolation would indeed lead to a higher AF recurrence rate.
Since no data exist on the time course of the deployed ablation lines. Do patients with recurrences of AF always have PV reconduction ? Vice versa, it also remains unclear if all patients with stable sinus rhythm do experience this effect based on longterm PV isolation. To assess the significance of the time course of PV isolation, the proposed study protocol consists therefore of an invasive re-evaluation of all primarily ablated pts scheduled after 3 months of follow-up regardless of arrhythmia recurrence to investigate PV conduction properties.
Finally, patients with symptomatic AF who underwent intensified ECG monitoring indicate that the standard clinical procedures (assessment of symptoms and surface ECG recordings at long intervals) are not sufficient to detect recurrent AF. Therefore, daily ECG monitoring is planned in this trial to detect asymptomatic episodes of AF.
The proposed study protocol aims to investigate in prospective, randomized fashion the significance of complete versus incomplete PV isolation by RFC-induced linear lesions. The ablation will be randomized to a linear encircling around the ipsilateral PVs with the endpoint of complete PV isolation proven by two circumferential mapping catheters versus the same ablation procedure which will be terminated instantaneously when total PV isolation occurs, thereby allowing at least one conduction gap along the isolation line. An invasive re-evaluation is scheduled after 3 months for all pts to assess longterm PV conduction properties.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Hamburg, Alemanha, 20246
- University Cardiac Center
-
Hamburg, Alemanha, 20099
- General Hospital St. Georg, Department of Cardiology
-
Münster, Alemanha, 48149
- University Hospital, Department of Cardiology
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Idiopathic paroxysmal symptomatic atrial fibrillation refractory to antiarrhythmic therapy
- Age 50 - 85 years
- Patient willing to participate in randomized trial and an invasive follow-up at month 3 (-6)
- Structural normal heart
- Patient willing and able to participate in 12 months follow-up period
- ECG documentation of atrial fibrillation (ECG, Holter, event recorders, etc) for at least one AF event in the prior year (related to symptomatic or asymptomatic episodes) with an average number of one episode per month
- Written informed consent of the patient
Exclusion Criteria:
- Patients who have had previous pulmonary vein ablation procedures Patients with atrial fibrillation secondary to a reversible cause
- Known presence of intracardiac or other thrombi
- Evidence of obstructive lung disease requiring bronchodilator therapy
- Pregnant females or those of child bearing potential who have not had a negative pregnancy test within 48 hours before treatment.
- Other medical illness (i.e. cancer, congestive heart failure) that may cause the patient to be non-compliant with the protocol, confound the data interpretation or is associated with limited life-expectancy (i.e., less than one year)
- History of bleeding diathesis or suspected pro-coagulant state contraindication to anticoagulation therapy
- Hyperthyroidism or hypothyroidism manifested clinically and in laboratory tests (TSH, T3, T4)
- Participation in a clinical trial within the last 30 days. Simultaneous participation in a registry (e.g. project AB1 of the AFNET) is permitted.
- Drug addiction or chronic alcohol abuse
- Legal incapacity, or other circumstances which would prevent the patient from understanding the aim, nature or extent of the clinical trial
- Evidence of an uncooperative attitude
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
---|---|
- Time to first recurrence of symptomatic AF with duration of more than 30 sec on trans-telephonic ECG monitoring or detection of asymptomatic AF defined as 2 consecutive recordings of AF during a minimum of 72 hours
|
Time to first recurrence of symptomatic AF with duration of more than 30 sec on trans-telephonic ECG monitoring or detection of asymptomatic AF defined as 2 consecutive recordings of AF during a minimum of 72 hours
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
---|---|
- Time to first occurrence of any documented relapse of atrial fibrillation
|
- Time to first occurrence of any documented relapse of atrial fibrillation
|
- Number and total duration of documented AF episodes
|
- Number and total duration of documented AF episodes
|
- Number of hospitalizations due to atrial fibrillation
|
- Number of hospitalizations due to atrial fibrillation
|
- Number of visits without hospitalization
|
- Number of visits without hospitalization
|
- Number of "serious adverse events of special interest"
|
- Number of "serious adverse events of special interest"
|
- Procedure parameters (duration, fluoroscopy, number of radiofrequency applications)
|
- Procedure parameters (duration, fluoroscopy, number of radiofrequency applications)
|
- Procedural costs (including the costs of re-ablation if AF recurrence occurs)
|
- Procedural costs (including the costs of re-ablation if AF recurrence occurs)
|
- Quality of life
|
- Quality of life
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Stephan Willems, MD, Universitätsklinikum Hamburg-Eppendorf
- Investigador principal: Günter Breithardt, MD, University of Münster
- Investigador principal: Karl-Heinz Kuck, MD, General Hospital St. Georg, Hamburg
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- AFNET-B04-1
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Fibrilação atrial
-
Ablacon, Inc.RecrutamentoFibrilação atrial | Arritmias Cardíacas | Arritmia | Flutter Atrial | Fibrilação Atrial, Persistente | Taquicardia Atrial | Arritmia Atrial | Fibrilação Atrial Paroxística | Fibrilação Atrial, Paroxística ou PersistenteEstados Unidos, Bélgica, Holanda, Tcheca
-
Vivek ReddyInscrevendo-se por conviteFibrilação e Flutter Atrial | Flutter Atrial Típico | Fibrilação Atrial, Paroxística ou PersistenteEstados Unidos
-
Angelo BivianoConcluído
-
Fundació Institut de Recerca de l'Hospital de la...RecrutamentoArritmia Atrial | Fibrilação e Flutter Atrial | Fibrilação Atrial RecorrenteEspanha
-
Adagio MedicalRecrutamentoFibrilação atrial | Flutter Atrial | Fibrilação Atrial Paroxística | Fibrilação Atrial PersistenteHolanda, Alemanha, Bélgica
-
Johannes Gutenberg University MainzBoehringer Ingelheim; Atrial Fibrillation NetworkRescindidoFibrilação Atrial ou Flutter Atrial | Trombose do Apêndice Atrial EsquerdoAlemanha
-
Abbott Medical DevicesRecrutamentoFibrilação atrial | Fibrilação Atrial Paroxística | Fibrilação Atrial Persistente | Arritmia AtrialEstados Unidos, Austrália, Bélgica, Alemanha, Espanha, Holanda, França, Áustria, Canadá, Tcheca, Itália, Reino Unido
-
St. George's Hospital, LondonRecrutamentoFibrilação atrial | Fibrilação Atrial, Persistente | Fibrilação Atrial Persistente | Arritmia AtrialReino Unido
-
R-PharmFSBI "National Medical Research Center of Cardiology named after academician...ConcluídoFlutter Atrial | Fibrilação Atrial Paroxística | Fibrilação Atrial PersistenteFederação Russa
-
Barts & The London NHS TrustAtriCure, Inc.Ainda não está recrutandoFibrilação Atrial, Persistente | Fibrilação Atrial Persistente | Arritmia Atrial | Átrio; FibrilaçãoReino Unido
Ensaios clínicos em Pulmonary vein ablation
-
Abbott Medical DevicesRecrutamentoTaquicardia Atrial | Arritmia Atrial | Átrio; FibrilaçãoEstados Unidos
-
Shaare Zedek Medical CenterMedtronicDesconhecidoHOCM, Cardiomiopatia Hipertrófica Obstrutiva
-
Medtronic Cardiac Rhythm and Heart FailureConcluídoFibrilação atrialEstados Unidos, Canadá, Espanha, Japão, Holanda, Bélgica, Austrália, Áustria, França
-
Farapulse, Inc.Ativo, não recrutando
-
CSA Medical, Inc.RescindidoDoenças Pulmonares Obstrutivas | Granulomatose de Wegener | Sarcoidose | Papilomatose Respiratória Recorrente | RinoscleromaEstados Unidos
-
Pier LambiaseUniversity Hospital Southampton NHS Foundation Trust; The Royal Bournemouth...ConcluídoFibrilação atrialReino Unido
-
CSA Medical, Inc.RescindidoCâncer | Neoplasias pleuraisEstados Unidos
-
Insel Gruppe AG, University Hospital BernUniversity of BernAtivo, não recrutandoFibrilação Atrial ParoxísticaSuíça
-
University of AdelaideBoston Scientific Corporation; Medtronic; Abbott Medical DevicesConcluídoInsuficiência cardíaca | Fibrilação atrialAustrália, Reino Unido, Nova Zelândia, Malásia, Alemanha
-
CSA Medical, Inc.RescindidoCâncer de pulmão | MesoteliomaEstados Unidos